1ABCD2 Score — Stroke Risk Reference
| Score | Risk Category | 2-Day Stroke Risk | 7-Day Stroke Risk | Action |
|---|---|---|---|---|
| 0–3 | Low | ~1% | ~1.2% | Urgent outpatient clinic within 24h |
| 4–5 | Moderate | ~4% | ~5.9% | Same-day specialist review. Do not discharge without assessment |
| 6–7 | High | ~8% | ~11.7% | Admission recommended. Immediate investigation |
Urgent Investigation for ALL TIA Patients (AHA/ASA 2021)
The ABCD2 score identifies risk but all TIA patients warrant urgent investigation regardless of score. The EXPRESS and SOS-TIA trials showed that rapid same-day treatment reduced 90-day stroke risk by 80%.
- Brain imaging: MRI with DWI within 24h (preferred) — identifies acute infarct in ~50% of TIAs confirming stroke diagnosis. CT head if MRI unavailable or contraindicated
- Vascular imaging: CT angiography or carotid duplex — urgent if anterior circulation TIA. Carotid stenosis >50% = surgery within 2 weeks (CEA or stenting)
- Cardiac monitoring: ECG, 24-72h Holter (or prolonged monitoring if cryptogenic) — AF found in 10–15% of TIA patients
- Bloods: FBC, ESR, glucose, lipids, HbA1c, coagulation screen
- Echocardiography: If cardioembolic source suspected (AF, valvular disease, young patient)
Immediate Secondary Prevention — Start Within Hours
- Dual antiplatelet therapy (DAPT): Aspirin 300 mg loading dose IMMEDIATELY + Clopidogrel 300 mg loading dose. Then aspirin 75 mg + clopidogrel 75 mg daily for 21 days (POINT trial / CHANCE trial). After 21 days: aspirin 75 mg alone long-term
- Statin: Start high-intensity statin immediately — atorvastatin 40–80 mg OD. Target LDL <1.8 mmol/L (70 mg/dL)
- Blood pressure: If SBP >140 mmHg, start/optimise antihypertensive within 24h. Target <130/80 mmHg long-term. Do not lower aggressively in acute phase
- Anticoagulation: If AF confirmed — start DOAC after ruling out haemorrhage on imaging. Do not give DAPT if anticoagulating
- No tPA: Thrombolytics are NOT recommended for TIA (symptoms fully resolved)
Limitations of ABCD2 Score
- ABCD2 does not replace clinical judgement — even a score of 0–3 does not make TIA "safe" to discharge without investigation
- ABCD2 was not designed to differentiate TIA from TIA mimics (hypoglycaemia, migraine aura, Todd's paresis, functional disorder)
- DWI-positive lesion on MRI is a better predictor of early stroke than ABCD2 score alone
- Crescendo TIA (≥2 TIAs in 1 week): very high risk regardless of ABCD2 score — treat as stroke emergency
2Frequently Asked Questions
3Related Calculators
4About the ABCD2 Score — TIA Risk Stratification
The ABCD2 score was developed to help clinicians stratify the short-term stroke risk after a transient ischaemic attack (TIA) and prioritise urgent investigation and treatment. TIA is a medical emergency — the risk of stroke is highest in the first 48 hours, with approximately 10-15% of TIA patients suffering a stroke within 3 months if untreated. Early secondary prevention can reduce this risk by up to 80%.
Despite its widespread use, the ABCD2 score has significant limitations and is no longer the primary triage tool in many high-income country guidelines. It does not capture high-risk TIA features such as atrial fibrillation, significant carotid stenosis, or DWI-positive MRI lesions — all of which independently predict high early stroke risk regardless of ABCD2 score. Current NICE (2019) and ESO guidelines recommend urgent specialist TIA clinic assessment within 24 hours for all TIA patients.
In the Indian context, TIA management is complicated by limited access to MRI and specialist neurology services at secondary care level. ABCD2 remains useful for triage in resource-limited settings — patients with score >=4 should be prioritised for urgent referral. All TIA patients, regardless of ABCD2 score, should receive immediate aspirin 300 mg, statin therapy, and blood pressure control pending specialist review.
Medical disclaimer: This calculator is for educational and clinical decision-support purposes only. It does not replace clinical judgment or specialist consultation. RxMedCalc is not liable for clinical decisions made solely on this tool.